The FDA has approved Gattex (teduglutide), from NPS Pharma, for subcutaneous use for the treatment of adult patients with Short...
Gattex/Revestive (teduglutide), from NPS Pharma, offers significant relief for patients with Short-Bowel Syndrome intestinal failure who are reliant on intravenous...
Takeda Pharmaceuticals announced that the FDA approved extending the indication of Gattex (teduglutide) for injection to pediatric patients 1 year...
The FDA Gastrointestinal Drugs Advisory Committee voted unanimously to recommend approval of Gattex (teduglutide) from NPS Pharma. It voted 12-0...
Shire plc announced that the FDA has accepted for filing the supplemental new drug application to extend the indication of...
Shire plc and NPS Pharmaceuticals, Inc. announced that the companies have entered into a merger agreement pursuant to which Shire...
Takeda Pharmaceutical Company Limited and NPS Pharmaceuticals, Inc. jointly announced that the European Commission (EC) has granted European market authorization...
Shire has announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive...